Atea Pharmaceuticals Announced The Presentation Of New Phase 1, In Vitro And In Vivo Data That Demonstrate Key Profile Attributes Of Atea’s Lead Drug Candidate, Bemnifosbuvir, For Covid-19 And Hepatitis C
Low risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies
Bemnifosbuvir retains activity against all SARS-CoV-2 variants of concern evaluated as well as
